IL145722A0 - Pharmaceutical composition comprising growth hormone and interferon - Google Patents

Pharmaceutical composition comprising growth hormone and interferon

Info

Publication number
IL145722A0
IL145722A0 IL14572200A IL14572200A IL145722A0 IL 145722 A0 IL145722 A0 IL 145722A0 IL 14572200 A IL14572200 A IL 14572200A IL 14572200 A IL14572200 A IL 14572200A IL 145722 A0 IL145722 A0 IL 145722A0
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
interferon
growth hormone
ifn
produce
Prior art date
Application number
IL14572200A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL145722A0 publication Critical patent/IL145722A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL14572200A 1999-04-08 2000-03-20 Pharmaceutical composition comprising growth hormone and interferon IL145722A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99106929A EP1043027A1 (fr) 1999-04-08 1999-04-08 Traitement combiné de l'esclerose multiple avec l'interferon et l'hormone de croissance
PCT/EP2000/002443 WO2000061176A2 (fr) 1999-04-08 2000-03-20 Traitement combine de la sclerose en plaques

Publications (1)

Publication Number Publication Date
IL145722A0 true IL145722A0 (en) 2002-07-25

Family

ID=8237920

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14572200A IL145722A0 (en) 1999-04-08 2000-03-20 Pharmaceutical composition comprising growth hormone and interferon

Country Status (9)

Country Link
US (1) US6869600B1 (fr)
EP (2) EP1043027A1 (fr)
JP (1) JP2002541211A (fr)
AT (1) ATE311897T1 (fr)
AU (1) AU776181B2 (fr)
CA (1) CA2365070A1 (fr)
DE (1) DE60028559T2 (fr)
IL (1) IL145722A0 (fr)
WO (1) WO2000061176A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002246619A1 (en) * 2000-12-08 2003-06-23 Neuronz Limited Use of insuline-like growth factor-i for promoting remyelination of axons
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
ATE435852T1 (de) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US20100239528A1 (en) * 2007-07-20 2010-09-23 Stem Cell Therapeutics Corp. Treating or Ameliorating a Neuroinflammatory or Demyelinating Disorder with Prolactin and Interferon-Beta
KR20180017232A (ko) * 2008-06-20 2018-02-20 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
US8691790B2 (en) * 2009-07-27 2014-04-08 James Layne Boucher Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
EP2670406B1 (fr) * 2011-12-21 2015-09-02 InnoBioscience, LLC Thérapie combinée par un interféron beta et des andrographolides destinés à la sclérose en plaques
CA2899961C (fr) * 2013-02-14 2022-08-09 Cornell University Methodes de protection contre la sclerose en plaques et methodes pour la traiter

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898856A (en) * 1984-10-29 1990-02-06 Chaovanee Aroonsakul Method for treating central nervous system diseases
CA1320905C (fr) * 1986-11-06 1993-08-03 Joseph M. Cummins Traitement d'affections immuno-resistantes
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
JPH06503320A (ja) * 1990-10-25 1994-04-14 ジェネンテク，インコーポレイテッド 再活性化酸素種に対する防御剤の使用
US5426096A (en) * 1992-03-18 1995-06-20 Soenksen; Peter Use of human growth hormone
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
US6024734A (en) * 1994-03-31 2000-02-15 Brewitt; Barbara A. Treatment methods using homeopathic preparations of growth factors
US6297212B1 (en) * 1994-05-31 2001-10-02 Gregory M. Fahy Growth hormone therapy and related methods and pharmaceutical compositions
US6187750B1 (en) * 1999-08-25 2001-02-13 Everyoung Technologies, Inc. Method of hormone treatment for patients with symptoms consistent with multiple sclerosis

Also Published As

Publication number Publication date
AU776181B2 (en) 2004-09-02
CA2365070A1 (fr) 2000-10-19
JP2002541211A (ja) 2002-12-03
ATE311897T1 (de) 2005-12-15
EP1043027A1 (fr) 2000-10-11
WO2000061176A3 (fr) 2001-01-25
AU3658400A (en) 2000-11-14
DE60028559T2 (de) 2006-10-05
EP1165118A2 (fr) 2002-01-02
US6869600B1 (en) 2005-03-22
EP1165118B1 (fr) 2005-12-07
DE60028559D1 (de) 2006-07-20
WO2000061176A2 (fr) 2000-10-19

Similar Documents

Publication Publication Date Title
CA2245938A1 (fr) Therapie combinee pour l'elimination de l'arn du vhc decelable chez les patients atteints d'une infection chronique due au virus de l'hepatite c
CS318089A3 (en) Antiviral and antibacterial agent
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
HU9602937D0 (en) Compositions comprising dna damaging agents and p53
CA2183871A1 (fr) Accelerateur de croissance des thrombocytes
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
ZA95743B (en) Therapeutic agents
MY109309A (en) Improvements in or relating to somatostatins
PL335979A1 (en) Antitussive compositions
IL161889A0 (en) Method for treating diseases with omega interferon
ZA984947B (en) Pharmaceutical use
GR3036774T3 (en) Compositions containing G-CSF and TNF binding protein.
GEP20022672B (en) Pharmaceutical Composition
WO2000061176A3 (fr) Traitement combine de la sclerose en plaques
JP2003514025A5 (fr)
NZ332105A (en) Medicaments including human growth hormone for the treatment of type II diabetes and metabolic syndrome
MY105798A (en) Treatment of leukocyte dysfunction with gm-csf.
CA2108330A1 (fr) Stimulateur de l'effet anti-anemique de l'erythropoietine et methode d'augmentation de cet effet
EP1023901A4 (fr) Produit d'amelioration de l'effet curatif sur l'hepatite c et son application
WO1990004977A3 (fr) Traitement de condylomes genitaux a l'aide d'une combinaison d'azote liquide et d'interferon alpha humain d'adn de recombinaison
NZ514629A (en) PEGylated interferon-alpha administered at about 4.5- 9.0 micrograms/kg/week as a renal cell carcinoma treatment
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
PT1007085E (pt) Utilizacao da hormona de crescimento em composicoes para o tratamento da resistencia a insulina no coracao
CA2097878A1 (fr) Agent therapeutique pour la neutropenie
WO1999013894A3 (fr) Utilisation d'ifn-alpha et d'amantadine dans le traitement de l'hepatite c chronique